Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics

BACKGROUND: In ∼3%-5% of patients with metastatic disease, tumor origin remains unknown despite modern imaging techniques and extensive pathology work-up. With long diagnostic delays and limited and ineffective therapy options, the clinical outcome of patients with cancer of unknown primary (CUP) re...

Descripción completa

Detalles Bibliográficos
Autores principales: Schipper, L.J., Samsom, K.G., Snaebjornsson, P., Battaglia, T., Bosch, L.J.W., Lalezari, F., Priestley, P., Shale, C., van den Broek, A.J., Jacobs, N., Roepman, P., van der Hoeven, J.J.M., Steeghs, N., Vollebergh, M.A., Marchetti, S., Cuppen, E., Meijer, G.A., Voest, E.E., Monkhorst, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808446/
https://www.ncbi.nlm.nih.gov/pubmed/36463731
http://dx.doi.org/10.1016/j.esmoop.2022.100611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808446/
https://www.ncbi.nlm.nih.gov/pubmed/36463731
http://dx.doi.org/10.1016/j.esmoop.2022.100611

Ejemplares similares